Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on April 29, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Small Business Subcontracting Participation (Future Contract Planning)

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
DIBBS
Measles, Mumps, and Rubella (MMR) Vaccine Supply and DeliveryThe contract entails the supply and delivery of three units of Measles, Mumps, and Rubella vaccine to a U.S. Navy vessel at a forward operating base destination, with strict requirements for traceable express shipping and full compliance with established medical handling standards. The contractor is responsible for ensuring the vaccines remain viable throughout transit by adhering to temperature control, packaging, and documentation protocols mandated for biological materials. This is a subcontract under the Department of Defense, managed by the Defense Logistics Agency, with a NAICS code of 325414 indicating pharmaceutical preparation manufacturing. The delivery must be completed in accordance with military logistics guidelines, and all shipping records must maintain a verifiable chain of custody from origin to final receipt aboard the vessel. The contract was posted on August 9, 2026, and the place of performance is tied to a military operational location, though specific geographic details are not provided. The award reference number SPE2DX25D8022 and delivery identifier SPE2D926F8119 are linked to the official DLA procurement system, underscoring the mission-critical nature of timely and secure delivery. While the solicitation number is not listed, the subcontract structure suggests coordination with a prime contractor to fulfill the DOD’s medical readiness requirements. All activities must comply with federal regulations governing vaccine distribution and military supply chain integrity.
Defense Logistics Agency

POSTED

about 1 month ago

DEADLINE

N/A

AI Contract Overview

Show more

Small businesses are invited to express interest in potential future subcontracting opportunities related to the supply, distribution, or technical support of reagents, contingent upon the award of a formal contract resulting from this market research initiative. The effort, led by the FDA Office of Acquisition and Grant Services under the U.S. Department of Health and Human Services, targets the North American Industry Classification System code 325414, which corresponds to medical and diagnostic laboratory reagent manufacturing. Participation is not a guarantee of a subcontract award but serves as a foundational step to identify capable small business vendors for inclusion in future procurement planning. Responses must be submitted by May 7, 2026, at 8:00 PM Eastern Time to ensure consideration, and while no formal solicitation number or set-aside designation has been assigned, the initiative is structured to enhance small business engagement in the federal supply chain without requiring immediate performance or financial commitment from respondents.

General Info

Small businesses may express interest in future reagent subcontracting opportunities with FDA by May 7, 2026.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

NAICS

325414 - Biological Product (except Diagnostic) ManufacturingView NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

This scope was carved out of 75F40126SSN134073.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Luminex magnetic carboxylated microsphere beads, or equivalent

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Opportunity for small businesses to participate in future subcontracting arrangements for reagent supply, distribution, or technical support if a formal contract is awarded based on this market research.

More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

Same awarding agency

NAICS: 541714
New
Federal
Human Hindbrain Organoid Functional Assay Services.
Solicitation # RFQ_CDR-2026-135968
The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 15 hours ago

DEADLINE

in 5 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS